AbbVie records $4B impairment on Stemcentrx deal
As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will record a $4 billion impairment charge on its 2016 acquisition of Stemcentrx Inc.
AbbVie paid $5.8 billion up front for Stemcentrx and its cancer compound Rova-T rovalpituzumab tesirine...
BCIQ Company Profiles
BCIQ Target Profiles